Article Version 1 Preserved in Portico This version is not peer-reviewed
Covid-19 Seroprevalence - Do the Results Advance the Aims?
Version 1 : Received: 25 August 2020 / Approved: 27 August 2020 / Online: 27 August 2020 (12:47:12 CEST)
How to cite: Almogy, G. Covid-19 Seroprevalence - Do the Results Advance the Aims?. Preprints.org 2020, 2020080622. https://doi.org/10.20944/preprints202008.0622.v1. Almogy, G. Covid-19 Seroprevalence - Do the Results Advance the Aims?. Preprints.org 2020, 2020080622. https://doi.org/10.20944/preprints202008.0622.v1.
Seroprevalence studies suggest that the number of PCR-confirmed COVID-19 cases is significantly smaller than the true number of infections. I study logintidual seroprevalence data from 7 sites across the US, from early April 2020 to June 27. I show that not only COVID-19 seroprevalence does not seem to increase over time, there is no clear association between the number of cases reported during a period and the change in seroprevalence during the same time. I conclude that as they are, seroprevalence studies can only be used in the qualitative sense and distinguish between populations with no COVID-19 exposure, to those populations where the virus had already started spreading.
Serology; Seroprevalence; Humoral response; COVID-19; serosurvey; epidemiology
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.Leave a public comment
Send a private comment to the author(s)